Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
about
RECQL5 cooperates with Topoisomerase II alpha in DNA decatenation and cell cycle progressionGlutathione S-transferase M1 null genotype: lack of association with tumour characteristics and survival in advanced breast cancer.High-definition DNA methylation profiles from breast and ovarian carcinoma cell lines with differing doxorubicin resistanceAssociations between clinicopathological prognostic factors and pAkt, pMAPK and topoisomerase II expression in breast cancer.Overexpression of ErbB2 in cancer and ErbB2-targeting strategies.HER-2/neu and topoisomerase IIalpha in breast cancer.Predictive value of topoisomerase II alpha immunostaining in urothelial bladder carcinomaTOP2A amplification in the absence of that of HER-2/neu: toward individualization of chemotherapeutic practice in breast cancerTargeted therapy in breast cancer: the HER-2/neu gene and protein.Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.DNA topoisomerase IIalpha expression and the response toprimary chemotherapy in breast cancer.The significance of Epstein Barr virus (EBV) & DNA topoisomerase II alpha (DNA-Topo II alpha) immunoreactivity in normal oral mucosa, oral epithelial dysplasia (OED) and oral squamous cell carcinoma (OSCC).Resistance to chemotherapy in cancer: a complex and integrated cellular response.A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer.Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?Optimal adjuvant chemotherapy in breast cancer: selection of agents.Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2/NEU testing.Aberrations of ERBB2 and TOP2A genes in breast cancer.Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer.Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes.HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support.Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial.Topoisomerase II-alpha expression in different cell cycle phases in fresh human breast carcinomas.Genomic imbalances detected by comparative genomic hybridization are prognostic markers in invasive ductal breast carcinomas.The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to chemotherapy: a retrospective immunohistochemical study.Role of proliferation in HER2 status predicted response to doxorubicin.Can patients' likelihood of benefiting from primary chemotherapy for breast cancer be predicted before commencement of treatment?Topoisomerase IIalpha as a prognostic factor in mantle cell lymphoma.High topoisomerase IIalpha expression associates with high proliferation rate and and poor prognosis in oligodendrogliomas.HER2 positivity may confer resistance to therapy with paclitaxel in breast cancer cell lines.Topoisomerase II-alpha gene deletion is not frequent as its amplification in breast cancer.Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
P2860
Q24293748-41138C1B-DD10-47C6-88D2-9C40AE9539B7Q24791151-8A695566-E20F-40EC-AF19-C3C4876A8514Q28474284-02CD03EA-10FE-45C8-B72E-3303451C3719Q33816025-60A4B600-5A56-4156-9783-DE16979FBE29Q33931164-EFDE746D-F5A7-452E-9B5F-B020ACA43A43Q35130680-6E0FAF84-747C-4E53-A2BD-C65EEDF77B83Q35398592-B8777C48-88DD-4850-AD4C-6003EF71F23DQ35584659-A1F3942D-6340-4B9E-A954-8D5B7AD2252DQ35648508-E6263050-9DF8-4FB1-A20C-D41EC64028C4Q35809752-F9AEB3F8-CD55-4057-AC1D-CE3899A72630Q36648223-DEA9AE4A-09EF-432B-81D3-121CB2A6E6C6Q37032422-53D97EE7-DBCC-4EB7-B160-DEF328242730Q37079652-74DFB59C-DACF-4B13-988B-7A9575F50450Q37458322-09505253-FEBB-461D-80AB-2A284F1E136BQ37989074-91A22D06-2DA6-4E18-B982-CC22A74AF8D3Q38235713-30337B21-D093-4A26-B8A2-BEC8D83CA949Q38455433-17BDF33C-C9F6-4A38-8613-60D5E86FA24DQ39769567-B9E553C9-B784-4C28-AF55-4F7F4D0BA8F2Q42486311-5C35142D-B7D9-427C-8A6F-DE32A5C8193DQ43062153-32B4C9E0-2E1C-454F-A9A3-A9C2C4293998Q43690747-EACF02E5-B2BB-4358-8E18-998CCE82AF87Q43712233-7F4CF298-2A91-431E-9E18-BA60E172B94BQ43993916-33F78B6E-232B-4C06-AAF7-02B14885A7A2Q44016601-F7F7726A-DE81-4F09-A218-5AD4A6A18163Q44225442-358BBBDF-7EC1-4A82-9DCA-C7D97C5A38A3Q44415276-53B540E8-B80A-4AA1-99E5-94BE778FB837Q45023676-F5ECE082-9F20-4B83-9B05-C5AC17144AE8Q47330973-DFA56E82-05FB-4852-80AC-59B612BB4430Q49142324-BB5C0D3E-1633-4142-89F8-4D5593DF81AFQ50643855-CE2B430B-73F3-41CE-B14E-E71EFC9743CEQ53603097-22B891F4-5254-4502-9834-9EDAB8187AEAQ54577077-AFE50D3C-8833-4887-BD0B-D4304D070AC1
P2860
Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Predictive value of topoisomer ...... apy in advanced breast cancer.
@ast
Predictive value of topoisomer ...... apy in advanced breast cancer.
@en
type
label
Predictive value of topoisomer ...... apy in advanced breast cancer.
@ast
Predictive value of topoisomer ...... apy in advanced breast cancer.
@en
prefLabel
Predictive value of topoisomer ...... apy in advanced breast cancer.
@ast
Predictive value of topoisomer ...... apy in advanced breast cancer.
@en
P2093
P2860
P356
P1476
Predictive value of topoisomer ...... apy in advanced breast cancer.
@en
P2093
Järvinen TA
Kuukasjärvi T
P2860
P2888
P304
P356
10.1038/BJC.1998.377
P407
P577
1998-06-01T00:00:00Z